Market open
MiNK Therapeutics/$INKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Ticker
$INKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23
ISIN
US6036932019
Website
INKT Metrics
BasicAdvanced
$30M
-
-$2.86
0.16
-
Price and volume
Market cap
$30M
Beta
0.16
52-week high
$13.79
52-week low
$4.56
Average daily volume
4.4K
Financial strength
Current ratio
0.717
Quick ratio
0.658
Long term debt to equity
-25.144
Total debt to equity
-25.144
Management effectiveness
Return on assets (TTM)
-137.35%
Return on equity (TTM)
57.30%
Valuation
Price to book
-1.52
Price to tangible book (TTM)
-1.52
Price to free cash flow (TTM)
-2.962
Growth
Earnings per share change (TTM)
-56.27%
3-year earnings per share growth (CAGR)
-37.32%
INKT News
AllArticlesVideos
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
GlobeNewsWire·5 hours ago
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GlobeNewsWire·1 week ago
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $30M as of May 15, 2025.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of May 15, 2025.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.